Simon Hollingsworth, Vice President and Global Franchise Head at AstraZeneca, has both delivered an exceptional portfolio of commercial developments and engaged extensively in the UK’s academic translational world.
He has pioneered application of companion diagnostic-driven developments in broadening the application of the PARP inhibitor Olaparib, extending utility far beyond BRCA mutant cancers. He has delivered Global regulatory approvals in metastatic breast and high-risk early breast cancer, metastatic pancreatic cancer, HRR-mutated and biomarker unselected metastatic prostate cancer, and HRD ovarian cancer.
He has been exemplary working across the historic boundaries of commercial and academic translational research, reflecting his passion to break these boundaries and see the community working together.